Our Strategy & Vision

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in “precision” medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company’s business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx’s four classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group—such as those in ValiRx’s pipeline—promise to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market (“AIM”) of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

ValiRx operates through the following divisional companies:


ValiPharma is a biopharmaceutical company focused on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer.

Currently, ValiPharma is primarily focused on two drug candidates in both clinical and late stage pre-clinical development for three indications – androgen independent prostate cancer (VAL201), hormone refractory prostate cancer (VAL201) and endometriosis (VAL301).

  • VAL201– VAL201 is a peptide with a unique mechanism of action, which was first developed by academics partly with support from Cancer Research UK. It has performed well in its Phase l/ll Clinical Trial in patients with advanced prostate cancer (APC) and as confirmed in June 2016, VAL201 is well tolerated and safe. Since then, VAL201 not only continues to show no drug-related safety concerns, but it also demonstrates early signs of activity in APC.
  • VAL301 – The Company continues with the development of VAL301, which is the proposed reformulation of VAL201 for a new indication, endometriosis. This is a gynaecological condition, characterised by endometrial-like tissue found outside of the uterine cavity. Endometriosis is a chronic and debilitating condition and it represents one of the major causes of female infertility. Pre-clinical data suggests that VAL301 will provide protection from the oestrogenic effects on uterine tissue, whilst maintaining bone density and fertility – a potentially significant development in the medical treatment of endometriosis and other gynaecological conditions.


ValiFinn’s specialist competency lies in epigenomics, a rapidly advancing field that enables pairing a prognostic and/or predictive biomarker with a targeted drug. This is a key part of personalised medicine, particularly in cancer patients. The Company is actively discovering, developing, and validating functional biomarkers with high specificity and sensitivity from its 5 families of patents and patent applications and related intellectual property. These are diagnostic markers of inhibition of signaling pathways, which are target sites for novel drugs to treat cancer and predictive markers of disease progression. This complementary biomarkers business, which identifies the presence of tumour markers at their early onset
is a key and increasingly exciting field within our industry and is one of the fastest growing areas of cancer research and diagnosis. This is because the detection of malignant cells as early as possible is a key challenge in cancer diagnosis and does have a significant impact on the future survival of patients.


ValiSeek is ValiRx’s joint venture company with Tangent Reprofiling Limited (a SEEK group company), which was formed in 2014 and has progressed product VAL401 through pre-clinical development and into a Phase II clinical trial for the treatment of lung cancer. VAL401 is a reformulation of Risperodone which has a well established safety record derived from decades of clinical use in the treatment of psychosis. The reformulation activates anti-cancer activity, and this is the subject of granted US patents (US 9,375,433 and US 9,072,743). VAL401 is currently being trialed as an oral treatment of late stage non-small cell lung, adenocarcinoma in a a Phase II Clinical Study in Tbilisi, Georgia. This study will measure the impact of VAL401 treatment on measures of progression-free survival, quality of life and overall survival of the patients as well as recording the pharmacokinetics, drug metabolism, safety and tolerability of the VAL401 formulation in comparison to historical clinical records for Risperidone.